Loading asset research
Dyne Therapeutics Inc. Common Stock
DYNNasdaq · USD · StocksQuote as of · Exchange session not verified$18.23
-1.03%
Today
DYN
Loading 1D prices…
Market cap
$3.4B
Volume
3.8M
52w high
$27.3152w low
$11.92Company profile
Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Waltham, MA, United States
Employees
289
Fiscal year end
1231
CIK
1818794
Session & valuation
Open$18.59
Previous close$18.42
Day high$18.74
Day low$17.94
30-day avg. volume2.6M
Outstanding shares186.7M
Diluted EPS-$3.47
Latest annual period
P/E (trailing)-5.25
P/E (forward)-5.46
Price / book4.30
Beta1.08
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc. Common Stock | $3.5B | $0.00 | — | -$1.53 | -1.46% | Buy |
| ABCLAbCellera Biologics Inc. Common Shares | $3.5B | $75.1M | -194.88% | -$0.49 | +4.16% | Buy |
| OGNOrganon & Co. Common Stock | $3.6B | $6.2B | +3.01% | $0.72 | +0.11% | Sell |
| LEGNLegend Biotech Corporation American Depositary Shares | $3.6B | $1B | -28.85% | -$1.62 | -2.89% | Buy |
| IDYAIDEAYA Biosciences Inc. Common Stock | $3.6B | $218.7M | -51.99% | -$1.28 | +0.32% | Buy |